Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Non-Current Deffered Revenue (2016 - 2018)

Ironwood Pharmaceuticals' Non-Current Deffered Revenue history spans 9 years, with the latest figure at $6.3 million for Q4 2018.

  • For Q4 2018, Non-Current Deffered Revenue rose 15.76% year-over-year to $6.3 million; the TTM value through Dec 2018 reached $6.3 million, up 15.76%, while the annual FY2018 figure was $6.3 million, 15.76% up from the prior year.
  • Non-Current Deffered Revenue for Q4 2018 was $6.3 million at Ironwood Pharmaceuticals, up from $6.1 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $10.1 million in Q1 2014 and bottomed at $557000.0 in Q4 2016.
  • The 5-year median for Non-Current Deffered Revenue is $6.2 million (2018), against an average of $6.1 million.
  • The largest annual shift saw Non-Current Deffered Revenue plummeted 91.29% in 2016 before it surged 878.28% in 2017.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $9.0 million in 2014, then decreased by 28.86% to $6.4 million in 2015, then tumbled by 91.29% to $557000.0 in 2016, then soared by 878.28% to $5.4 million in 2017, then grew by 15.76% to $6.3 million in 2018.
  • Per Business Quant, the three most recent readings for IRWD's Non-Current Deffered Revenue are $6.3 million (Q4 2018), $6.1 million (Q3 2018), and $6.1 million (Q2 2018).